###begin article-title 0
###xml 2 3 2 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 5 7 5 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Na+/H+ exchanger regulatory factor 1 inhibits platelet-derived growth factor signaling in breast cancer cells
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 20 21 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 23 25 23 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
The gene encoding Na+/H+ exchanger regulatory factor 1 (NHERF1) is a putative tumor suppressor gene that harbors frequent loss of heterozygosity (LOH) and intragenic mutations in breast carcinoma. The exact biologic activity of NHERF1 in mammary glands, however, remains unclear. It was recently proposed that NHERF1 forms a ternary complex with platelet-derived growth factor receptor (PDGFR) and phosphatase and tensin homolog (PTEN), linking NHERF1 suppressor activity to PDGF-initiated phosphoinositide-3 kinase (PI3K)/PTEN signaling.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 104 111 104 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 164 171 164 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 194 198 <span type="species:ncbi:10090">mice</span>
The effect of NHERF1 on the kinetics of PDGF-induced Akt activation was determined in cells with varied NHERF1 background. Levels of active Akt in mammary gland of NHERF1 knockout and wild-type mice were compared. We also examined how NHERF1 expression status affects cell sensitivity to PDGFR inhibitor. A plausible connection between NHERF1 and PTEN pathway was explored at the genetic level.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 431 438 431 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 1045 1052 1045 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 1173 1178 1173 1178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN </italic>
###xml 1181 1188 1181 1188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PI3KCA </italic>
###xml 389 394 <span type="species:ncbi:10090">mouse</span>
###xml 447 451 <span type="species:ncbi:10090">mice</span>
###xml 510 514 <span type="species:ncbi:10090">mice</span>
We showed that NHERF1, through its PDZ-I domain, interacts directly with the carboxyl-terminal tail of PTEN. Knocking down NHERF1 expression in Zr75.1 cells markedly delayed the turnover of PDGF-induced phospho-Akt. Conversely, NHERF1 over-expression in MCF10A cells led to accelerated phospho-Akt degradation. The slowed decay of phospho-Akt that resulted from NHERF1 loss was evident in mouse embryonic fibroblasts isolated from NHERF1 knockout mice. In agreement with this, mammary gland tissues from these mice exhibited markedly elevated phospho-Akt. The responses of breast cancer cells to PDGFR inhibition were also altered by changes in NHERF1 expression level. Zr75.1 cells with NHERF1 knockdown were more resistant to STI-571-induced apoptosis than parental cells. Similarly, over-expression of NHERF1 rendered MCF10A cells more sensitive to STI-571. NHERF1-induced apoptotic response relies on an intact PTEN pathway; over-expression of NHERF1 in MCF10A cells with PTEN knockdown did not affect STI-571 sensitivity. It was found that NHERF1 LOH-positive breast cancer cells had reduced NHERF1 expression. Interestingly, these cells more frequently had wild-type PTEN or PI3KCA gene than the LOH-negative lines.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 245 252 245 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 256 261 256 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN </italic>
###xml 265 271 265 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PI3KCA</italic>
Our data indicate that the interaction of NHERF1 with PTEN counterbalances PI3K/Akt oncogenic signaling and may affect how cells respond to PDGFR inhibition in breast cancer. The dependence of NHERF1 responses on PTEN and genetic segregation of NHERF1 and PTEN (or PI3KCA) alterations suggest that NHERF1 is an active component of the PTEN pathway. Collectively, our study indicates that the biologic activity of NHERF1 in mammary gland is related to PTEN signaling.
###end p 9
###begin p 10
See related editorial by Georgescu, 
###end p 10
###begin title 11
Introduction
###end title 11
###begin p 12
###xml 20 21 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 23 25 23 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 163 170 163 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 444 445 444 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 584 585 584 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 987 988 987 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 989 990 989 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1046 1047 1046 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1048 1049 1048 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1056 1057 1053 1054 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1079 1080 1076 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1081 1082 1078 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1124 1126 1121 1123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1332 1334 1326 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1335 1337 1329 1331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1509 1513 1503 1507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NF2 </italic>
###xml 1558 1562 1552 1556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NF2 </italic>
###xml 1632 1634 1626 1628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1635 1637 1629 1631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 136 141 <span type="species:ncbi:9606">human</span>
###xml 157 162 <span type="species:ncbi:9606">Human</span>
The gene encoding Na+/H+ exchanger regulatory factor 1 (NHERF1) (also known as EBP-50 or NHERF) is a candidate tumor suppressor gene in human breast cancer. Human NHERF1 cDNA encodes a protein of 358 amino acids in length. NHERF1 and its close homolog NHERF2 (also known as E3KARP or TKA1) share two modular structures: two tandem PDZ domains at the amino-terminus and an ezrin-radixin-moesin (ERM)-interacting domain at the carboxyl-terminus [1]. NHERF1 and NHERF2 are differentially expressed in mammalian tissues, with particularly high levels found in polarized epithelial cells [2]. NHERF1 acts as an important regulator and integrator of multiple signaling pathways by virtue of its ability to bind to a variety of proteins through its PDZ (PSD-95/Dlg/ZO1) domains and ERM-interacting domain. Via its PDZ domains, NHERF1 recognizes a carboxyl-terminal motif, D(S/T)XL, that is present in a number of transmembrane proteins, such as platelet-derived growth factor receptor (PDGFR) [3,4], cystic fibrosis transmembrane conductance regulator [5-7], beta2-adrenergic receptor [8,9], and sodium bicarbonate co-transporter [10]. NHERF1 also interacts with a variety of intracellular proteins, including phospholipase C-beta isoforms, G protein-coupled receptor kinase 6A, spleen tyrosine kinase (SYK) and Yes-associated protein 65 [11-15]. Via its carboxyl-terminal ERM-interacting domain, NHERF1 binds to ERM proteins, a family of actin cytoskeletal adaptors. One ERM family member is merlin, the product of NF2 tumor suppressor gene. Germline mutations of NF2 have been implicated in predisposition to meningiomas and schwanomas [16,17]. The amino-terminus of the ERM family proteins (ERM domain) binds to the ERM-interacting domain of NHERF1; this interaction may be important for NHERF1 functions through its connection of membrane transporters and actin cytoskeleton.
###end p 12
###begin p 13
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 209 216 209 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 308 315 308 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 401 408 401 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 479 481 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 760 767 760 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 891 898 891 898 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
The NHERF1 gene is located at 17q25.1. Loss of heterozygosity (LOH) at this locus occurs in more than 50% of breast tumors [15,18-23]. However, such allelic loss is infrequent in other tumor types; LOH at the NHERF1 locus occurred in fewer than 10% of colorectal and pancreatic cancer lines, suggesting that NHERF1 is specifically targeted during breast tumorigenesis [15]. We reported three cases of NHERF1 intragenic mutations in a panel of breast tumors pre-screened for LOH [15]; notably, all mutations were located at conserved residues of PDZ domains or ERM-interacting domain. These tumorigenic mutations interfere with NHERF1 binding to SYK or merlin (loss-of-function), suggesting their functional relevance to breast tumor initiation or progression. NHERF1 LOH positively correlates with aggressive features of breast tumors, including tumor size, grade and stage, indicating that NHERF1 plays a critical role in mammary carcinogenesis, in which its putative suppressor activity may be haplo-insufficient.
###end p 13
###begin p 14
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 316 318 316 318 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 548 550 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 649 651 649 651 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 846 848 846 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
Despite the genetic evidence available, the biologic activities of NHERF1 in mammary gland were unknown. The finding that the phosphorylation status of NHERF1 oscillated during the cell cycle implicated possible link of NHERF1 to tumor-related response [24]. Indeed, the fact that NHERF1 is a substrate for cdc2, a G2 to M phase cyclin-dependent kinase, suggests a role of NHERF1 in cell division [24]. Using the small interfering RNA (siRNA) method, we demonstrated increased growth of breast cancer cells when NHERF1 expression was knocked down [25]. The growth promotion effect that occurred in response to NHERF1 loss was due to an accelerated G1 to S transition, which was accompanied by elevated levels of cyclin E and phosphorylated Rb protein. This indicated that normal NHERF1 function may involve suppression of cell cycle progression [25].
###end p 14
###begin p 15
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 699 701 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 856 858 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 663 668 <span type="species:ncbi:10090">mouse</span>
Although the identity of the NHERF1-interacting partner responsible for the cell cycle regulatory effect remains unclear, a recent report [26] showed NHERF1 binding to the carboxyl-terminal tail (PDZ-binding motif) of phosphatase and tensin homolog (PTEN). The PDZ-binding motif of PTEN was also shown to interact with membrane-associated guanylate kinase family proteins, but the biologic significance of these bindings is not clear [27-29]. The interaction of NHERF1 with PTEN and PDGFR facilitates the formation of a ternary complex. Interestingly, this complex formation was found to offset PDGF-initiated phosphorylation of downstream targets such as Akt in mouse embryonic fibroblasts (MEFs) [26]. Activated Akt (by phosphorylation) plays a pivotal role in promoting cell survival, increasing cell invasiveness and overriding cell cycle checkpoints [30]. A possible activity of NHERF1 in counteracting the Akt pro-oncogenic pathway raises an attractive mechanism that explains NHERF1 tumor suppressor activity in mammary glands. Thus, in the present study we sought to determine whether the activity of NHERF1 is associated with a PTEN-dependent pathway in breast cells, and whether NHERF1 expressional status affects PDGF-stimulated downstream cell survival signaling as well as cell responses to PDGFR inhibition.
###end p 15
###begin title 16
Materials and methods
###end title 16
###begin title 17
Cell culture
###end title 17
###begin p 18
Breast cancer cell lines MCF7, MDA-MB-468, SKBr3, T47D, ZR75.1 and immortalized mammary epithelial line MCF10A were purchased from American Type Culture Collection (Manassas, VA, USA). All cell lines were cultured in recommended media.
###end p 18
###begin p 19
Cultured Zr75.1, MCF10A and MEF cells were incubated with serum-free media for 1 day. They were then treated with PDGF-BB (0.5 ng/ml; Millipore, Billerica, MA, USA) for 0 to 120 minutes before cells were harvested in 1x SDS sample buffer.
###end p 19
###begin title 20
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 16 20 <span type="species:ncbi:10090">mice</span>
NHERF1 knockout mice
###end title 20
###begin p 21
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 6 10 6 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 16 18 16 18 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 108 115 108 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 469 471 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 10 14 <span type="species:ncbi:10090">mice</span>
###xml 124 128 <span type="species:ncbi:10090">mice</span>
NHERF1+/- mice [31] were inbred to generate littermates of three genotypes. Duplex PCR was used to genotype NHERF1 knockout mice. A common forward primer (5'-ctctgtttattcccagaagga-3') was included in the PCR reaction, together with reverse primers for knockout (5'-caagctcttcagcaatatcac-3') and wild-type (5'-ggttctaccagacggataaac-3') genotypes that were expected to yield 2.4-kilobase and 1.4-kilobase products, respectively. PCR conditions were described previously [15].
###end p 21
###begin p 22
###xml 28 35 28 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 44 48 <span type="species:ncbi:10090">mice</span>
To harvest mammary gland of NHERF1 knockout mice, 10-week-old female littermates were killed by carbon dioxide inhalation. Mammary glands were collected and snap frozen at -80degreesC until use. Tissues were then ground while frozen in liquid nitrogen and lysed in 1x SDS sample buffer. The lysates were then subjected to immunoblotting.
###end p 22
###begin p 23
###xml 30 37 30 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 62 68 62 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 68 72 68 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 72 76 <span type="species:ncbi:10090">mice</span>
###xml 306 312 <span type="species:ncbi:9913">bovine</span>
To obtain MEF cells of varied NHERF1 genetic backgrounds, the NHERF1+/- mice were inbred. At embryonic days 12 to 14, the embryos were dissected to remove heads and internal organs. The remaining tissues were minced, trypsinized and plated in Dulbecco's medified Eagle's medium supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA). Genomic DNA was also harvested from MEF cells for genotyping. Early-passage MEF cells were then subjected to experimental treatment.
###end p 23
###begin title 24
DNA constructs
###end title 24
###begin p 25
###xml 98 105 98 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
To prepare recombinant retrovirus to knockdown NHERF1 expression, an siRNA sequence that targeted NHERF1 transcript was inserted into pBabe-U6-Puro (a gift from Dr Jinsong Liu, M.D. Anderson Cancer Center, Houston, TX, USA). Two oligonucleotides (5'-ggaaactgacgagttcttcaaagctttgaagaactcgtcagtttccctttttg-3' and 5'-aattcaaaaagggaaactgacgagttcttcaaagctttgaagaactcgtcagtttcc-3') were annealed and subcloned into pBabe-U6, creating pBabe-U6/NHERF-910-Puro. Similarly, oligonuclotides (5'-ggacgaactggtgtaatgatatgaagcttcatatcattacaccagttcgtccctttttg-3' and 5'-aattcaaaaagggacgaactggtgtaatgatatgaagcttcatatcattacaccagttcgtcc-3') were used to knock down PTEN expression (pBabe-U6/PTEN-Puro).
###end p 25
###begin p 26
GST-PTEN, pcDNA3.1-PTEN, and pcDNA3.1-PTEN-C124S were gifts from Dr Charles Sawyer (University of California, Los Angeles, CA, USA). To make a PTEN construct with deletion of the last six residues (TQITKV), PCR was conducted to introduce premature termination, using pcDNA3.1-PTEN as a template. This procedure created pcDNA3.1-PTEN-DeltaC.
###end p 26
###begin p 27
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 208 215 208 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 297 304 297 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
NHERF1 cDNA was obtained by reverse transcription from mRNA of a breast cancer cell line, SKBr3, and amplified by PCR. Reverse transcription PCR products were subcloned into a TA cloning vector (Invitrogen). NHERF1 cDNA was then subcloned into pcDNA3.1(+) (Invitrogen), generating pDNA3.1-NHERF1. NHERF1 cDNA was then enzymatically released from pcDNA3.1-NHERF1 and subcloned into pBabe-Puro, pBabe-Neo (Addgene, Cambridge, MA, USA), and pGEX2TK (GE Healthcare, Piscataway, NJ, USA), yielding pBabe-NHERF1-Puro, pBabe-NHERF1-Neo, and pGEX2TK-NHERF1, respectively. cDNA fragments encoding PDZ-I (residues 1 to 150), PDZ-II (residues 97 to 239), PDZ-I&II (residues 1 to 239), and carboxyl-terminus (residues 231-358) of NHERF1 were PCR-amplified and constructed to pcDNA3.1 or pGEX2TK. All constructs generated by PCR were verified by automated DNA sequencing.
###end p 27
###begin title 28
Retroviral infection
###end title 28
###begin p 29
Retroviral stocks were made by transfecting packaging cells (amphotropic Phoenix cells) with retroviral constructs (pBabe-U6-Puro, pBabe-U6-NHERF-910-Puro, pBabe-U6-PTEN-Puro, pBabe-Puro, pBabe-NHERF1-Puro, pBabe-Neo, and pBabe-NHERF1-Neo), using Fugene 6 (Roche Applied Science, Indianapolis, IN, USA).
###end p 29
###begin p 30
To prepare MCF10A cells over-expressing NHERF1, MCF10A cells were infected with NHERF1-Puro (or NHERF1-Neo for PTEN knockdown cells) recombinant retrovirus. Infected cells were selected by adding 1 to 5 mug/ml puromycin (or 600 mug/ml G418) to culture media. Surviving cells were assessed for NHERF1 expression by immunoblotting. MCF10A-NHERF1-Neo cells were further infected with PTEN-siRNA retrovirus to knockdown PTEN expression, which was determined by PTEN immunoblotting.
###end p 30
###begin p 31
The expression of NHERF1 in Zr75.1 and MDA-MB-468 cells was knocked down by using retrovirus-based siRNA method. Zr75.1 cells were infected with Babe-U6-NHERF-910-Puro retrovirus and subjected to puromycin (2 mug/ml) selection. NHERF1 expression was determined by immunoblotting.
###end p 31
###begin title 32
Glutathione S-transferase pull-down assays
###end title 32
###begin p 33
Glutathione S-transferase (GST) pull-down assays were used to assess the interaction of NHERF1 and PTEN. GST-PTEN or GST-NHERF1 and their derivatives were induced by isopropyl-beta-D-1-thiogalactopyranoside in pGEX2TK-transformed BL21 strain and purified with glutathione-Sepharose beads (GE Healthcare).
###end p 33
###begin p 34
###xml 110 119 110 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 171 178 171 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 181 186 181 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN </italic>
###xml 226 228 226 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
Radio-labeled full-length or defined segments of NHERF1 and full-length or truncated PTEN were synthesized by in vitro transcription from pcDNA3.1 plasmids containing the NHERF1 or PTEN cDNA and translated in the presence of [35S]methionine (T7 Quick TNT kit; Promega, Madison, WI, USA). The translation products were mixed with purified GST-PTEN or GST-NHERF1 immobilized on the beads. Pull-down assays were performed at 4degreesC for 1 hour in 1x binding buffer (20 mmol/l Tris [pH 7.5], 150 mmol/l NaCl, and 1% NP-40). The beads were then washed thoroughly with 1x binding buffer. Bound proteins were eluted by boiling in 1x SDS sample buffer, separated by SDS-PAGE. Ten per cent of the input TNT lysates was also run on the PAGE to determine relative binding capacity. The PAGE gel was then dried and exposed for autoradiography.
###end p 34
###begin p 35
###xml 311 312 311 312 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 314 316 314 316 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
GST pull-down assay was also used to determine whether endogenous PTEN or NHERF1 binds to recombinant NHERF1 or PTEN, respectively. MDA-MB-468, MCF7, and T47D cells were harvested by adding 1x lysis buffer (50 mmol/l Tris-HCl [pH 7.5], 150 mmol/l NaCl, 1 mmol/l EDTA, 1% Triton-X 100, 10 mmol/l NaF, 1 mmol/l Na3VO4 and 1x protease inhibitor cocktail [Sigma, St. Louis, MO, USA]). The cell lysates were then incubated with beads coated with GST fusion proteins. The incubation lasted for 2 hours at 4degreesC. The beads were then washed thoroughly with 1x binding buffer before being boiled in 1x SDS sample buffer. The eluted proteins were then subjected to NHERF1 or PTEN immunoblotting.
###end p 35
###begin title 36
Immunoprecipitation and immunoblotting
###end title 36
###begin p 37
###xml 272 273 271 272 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 275 276 274 275 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 354 358 <span type="species:ncbi:9925">goat</span>
###xml 473 477 <span type="species:ncbi:9925">goat</span>
To assess the interaction of PTEN with NHERF1 at the endogenous level, cultured MCF7 or Zr75.1 cells were lysed with 1x NETN buffer (20 mmol/l Tris-HCl [pH 7.5], 150 mmol/l NaCl, 1 mmol/l EDTA, 0.5% NP-40, 30 mug/ml aprotinin, 5 mmol/l PMSF, 25 mmol/l NaF, and 2 mmol/l Na3VO4). The soluble proteins (about 600 mug) were immunoprecipitated with 2 mug of goat IgG reactive to PTEN (N-19; Santa Cruz Biotechnologies, Santa Cruz, CA, USA) at 4degreesC overnight, using normal goat IgG as a control. The immunocomplex was collected by addition of 50 mul of agarose-conjugated protein G (Roche Applied Science) and detected with anti-NHERF1 antibody.
###end p 37
###begin p 38
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 240 245 <span type="species:ncbi:9606">human</span>
###xml 331 336 <span type="species:ncbi:10090">mouse</span>
Protein concentrations were measured by using BCA reagent. Lysates were then subjected to immunodetection of phospho-Akt (p-Akt) and total Akt. Immunoblottings were carried out essentially as described previously [32]. Antibodies used were human NHERF1 (EXBIO Praha, Vestec, Czech Republic), beta-actin (Santa Cruz Biotechnology), mouse NHERF1 (Affinity Bioreagents, Golden, CO, USA), PTEN (Millipore), caspase-3, phospho-Akt-Ser473, total Akt, and phospho-p70 S6 kinase-Thr421/Ser424 (Cell Signaling Technology, Danvers, MA, USA).
###end p 38
###begin title 39
MTT assays
###end title 39
###begin p 40
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assays were used to measure cell viability. Cells were seeded in 96-well cluster dishes at 5,000 cells/well with 100 mul complete medium. After overnight incubation, medium was replaced to include various concentrations of STI-571 (Novartis Pharmaceuticals). After 2 days of treatment, cells were fed 100 mul fresh medium that contained 1 mg/ml MTT (Sigma). The incubation lasted for 2 hours before the medium was removed and cells dissolved in 150 mul dimethyl sulfoxide. Absorbance was measured using a multiSkan plate reader (LabSystems, Waltham, MA, USA) at a wavelength of 570 nm. Each sample was processed in triplicate. Experiments were repeated at least three times.
###end p 40
###begin title 41
Results
###end title 41
###begin title 42
Interaction of NHERF1 and PTEN
###end title 42
###begin p 43
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 539 548 539 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 682 684 682 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 947 949 947 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1d</xref>
###xml 971 973 971 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1e</xref>
###xml 1365 1367 1365 1367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1f</xref>
###xml 1566 1568 1566 1568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1g</xref>
To verify that there is an interaction between NHERF1 and PTEN, we first used GST-PTEN (Figure 1a) to pull down NHERF1 from lysates of MCF7 and MDA-MB-468 cells. We found GST-PTEN, but not GST alone, to be associated with NHERF1 (Figure 1b). Of note, the quantity of full-length GST-PTEN bound to the beads was much lower than that of the GST control (Figure 1a). As a result, much less GST-PTEN was used in the experiments. To determine whether the interaction between NHERF1 and PTEN was direct, we conducted a GST pull-down assay using in vitro synthesized full-length NHERF1. GST-PTEN but not GST interacted directly with the full-length NHERF1 and the PDZ-I&II domains (Figure 1c). Thus, the PDZ-I&II domains of NHERF1 are likely to mediate this direct interaction. In reverse experiments, we used GST fusion of PDZ-I and -II domains (residues 1 to 239) or carboxyl-terminal half (CT; residues 231 to 358) of NHERF1 to pull down PTEN (Figure 1d). As shown in Figure 1e, GST-PDZ-I&II bound to PTEN from MCF7 and T47D cell lysates. In contrast, CT did not bind to PTEN, confirming that NHERF1 interacted with PTEN through its PDZ domains. To further assess whether the PDZ-I or the PDZ-II domain was responsible for PTEN association, we conducted a similar GST pull-down assay using GST-PDZ-I (residues 1 to 150) or GST-PDZ-II (residues 97 to 239) beads (Figure 1f). Although PDZ-II did not interact with PTEN, PDZ-I associated with PTEN at a level similar to that of PDZ-I&II, indicating that PDZ-I is responsible for the interaction of NHERF1 with PTEN (Figure 1g).
###end p 43
###begin p 44
###xml 74 78 74 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 215 219 215 219 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 381 382 381 382 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 384 386 384 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 505 509 505 509 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 630 632 630 632 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 800 804 800 804 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 900 904 900 904 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e) </bold>
###xml 1118 1122 1118 1122 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(f) </bold>
###xml 1211 1215 1211 1215 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(g) </bold>
###xml 1385 1389 1385 1389 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(h) </bold>
###xml 1461 1463 1461 1463 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 1671 1675 1671 1675 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(i) </bold>
###xml 1783 1787 <span type="species:ncbi:9925">goat</span>
The PDZ-binding motif of PTEN associates with the PDZ-I domain of NHERF1. (a) Coomassie-blue staining of glutathione S-transferase (GST)-phosphatase and tensin homolog (PTEN) fusion (arrow) and GST control protein. (b) GST pull-down assays. GST-PTEN beads were incubated with MCF7 or MDA-MB-468 cell lysates. The protein bound on beads was separated by SDS-PAGE and subjected to Na+/H+ exchanger regulatory factor 1 (NHERF1) immunoblotting. Ten per cent of the initial protein input was run side-by-side. (c) GST pull-down. The full-length NHERF1 or the PDZ-I&II domain protein was synthesized by TNT reaction in the presence of [35S]methionine. The labeled proteins were then incubated with GST or GST-PTEN. Components bound to GST fusion were separated by SDS-PAGE and detected by autoradiography. (d) Coomassie-blue staining of GST fusion of PDZ-I&II or the carboxyl-terminal half (CT) of NHERF1. (e) GST pull-down. Procedures were the same as those described for panel b except that MCF7 and T47D cells lysates, GST-PDZ-I&II and GST-CT were used in the reaction. Bound protein was detected by PTEN immunoblotting. (f) Coomassie-blue staining of GST fusion of PDZ-I or PDZ-II compared with that of PDZ-I&II. (g) NHERF1 interaction with PTEN through its PDZ-I domain. The experimental method was the same as that described for panel e except for the use of GST-PDZ-I and GST-PDZ-II. (h) PTEN binding to NHERF1 through its carboxyl-terminal PDZ-binding motif. 35S-labeled wild-type (WT) PTEN, a tumorigenic mutant (C124S), or a PTEN variant with deletion of the PDZ motif (delta C) were made by TNT reaction and evaluated for their binding to PDZ-I or PDZ-II of NHERF1. (i) Lysates from MCF7 and Zr75.1 cells were subjected to immunoprecipitation using anti-PTEN antibody or normal goat IgG. The NHERF1 protein was detected in the precipitated materials by immunoblotting. Twenty per cent of input lysates was run side-by-side.
###end p 44
###begin p 45
###xml 105 107 105 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1h</xref>
###xml 576 578 572 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1h</xref>
###xml 963 971 959 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1027 1029 1023 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1i</xref>
The direct interaction between PTEN and NHERF1 was also confirmed by pull-down assays using GST-PDZ and [35S]-labeled PTEN products. Consistent with earlier findings, the wild-type PTEN bound strongly to PDZ-I but very weakly to PDZ-II (Figure 1h). The interaction was not affected by a tumor-derived mutation (C124S). To determine whether the PDZ-binding motif in PTEN is required for its interaction with NHERF1, we made PTEN with a deletion of the last six amino acids (DeltaC). Pull-down assays, showing this PTEN mutant to be incapable of interacting with NHERF1 (Figure 1h), indicated that the PDZ-binding motif of PTEN is responsible for its binding to NHERF1. We further examined whether NHERF1 bound to PTEN at the endogenous expression level by using MCF7 and Zr75.1 cells that expressed high levels of NHERF1 and PTEN. Co-immunoprecipitation identified a significant interaction between the two proteins, demonstrating that NHERF1 associates with PTEN in vivo when they are expressed at the endogenous level (Figure 1i).
###end p 45
###begin title 46
NHERF1 affects cell responses to PDGF-initiated Akt phosphorylation
###end title 46
###begin p 47
###xml 129 135 129 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 135 139 135 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 143 149 143 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 149 153 149 153 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 218 224 218 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 224 228 224 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 240 247 240 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 372 378 372 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 378 382 378 382 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 386 392 386 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 392 396 392 396 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 585 591 585 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 591 595 591 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 671 677 671 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 677 681 677 681 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 715 717 715 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 815 822 815 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 919 921 919 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 1089 1091 1089 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 228 232 <span type="species:ncbi:10090">mice</span>
Expression of NHERF1 reportedly accelerates the decay of p-Akt induced by PDGF stimulation. We first verified this conclusion in NHERF1+/+ and NHERF1-/- MEFs isolated from 14-day embryos that resulted from crossing of NHERF1+/- mice. Their NHERF1 genetic status was determined by genotyping, and their NHERF1 protein expression was verified by immunoblotting (Figure 2a). NHERF1-/- and NHERF1+/+ MEFs were then subjected to treatment with PDGF ligands and harvested after 0 to120 minutes. PDGF initially induced p-Akt to similar levels in the two groups of MEFs (10 minutes). p-Akt in NHERF1-/- cells remained at high levels at 90 and 120 minutes, but the p-Akt level in NHERF1+/+ cells deminished markedly (Figure 2b). We repeated these experiments in two cell lines of breast origin. MCF10A cells over-expressing NHERF1 cDNA by retroviral infection exhibited a faster turnover of p-Akt than did control cells (Figure 3a). Likewise, knockdown of NHERF1 expression in Zr75.1 cells by retroviral infection with NHERF-910 siRNA decelerated the decay of p-Akt signals induced by PDGF (Figure 3b). In agreement with these findings, the phosphorylation status of an Akt downsream target, namely p70 S6 kinase, was consistent with p-Akt level in both MCF10A and Zr75.1 cells. These results agree with the working model that NHERF1 attenuates PDGF-initiated downstream survival signals by forming protein complex with PTEN and PDGFR.
###end p 47
###begin p 48
###xml 109 113 109 113 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 130 131 130 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 133 135 133 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 232 238 232 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 238 242 238 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 246 252 246 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 252 256 252 256 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 682 686 682 686 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 692 698 692 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 698 702 698 702 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 705 711 705 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 711 714 711 714 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 80 85 <span type="species:ncbi:10090">mouse</span>
###xml 188 193 <span type="species:ncbi:10090">mouse</span>
###xml 659 664 <span type="species:ncbi:10090">mouse</span>
NHERF1 deletion leads to increased stability of PDGF-stimulated p-Akt signal in mouse embryonic fibroblasts. (a) Genotyping and Na+/H+ exchanger regulatory factor 1 (NHERF1) expression of mouse embryonic fibroblast (MEF) cells with NHERF1+/+ and NHERF1-/- backgrounds. Left panel: duplex PCR was conducted to evaluate the genotypes, using the genomic DNA extracted from MEFs. Wild-type (WT) and knockout (Neo) alleles were expected to generate 1.4-kilobase and 2.4-kilobase products, respectively. Predicted genotypes are indicated. Right panel: NHERF1 expression in MEFs as measured by immunoblotting. Asterisks indicate bands from nonspecific reactivity to mouse NHERF1 antibody. (b) MEFs (NHERF1+/+ or NHERF1-/-) were serum starved and stimulated with platelet-derived grwoth factor-BB (0.5 ng/ml) for indicated periods before cells were harvested for phospho-Akt (p-Akt; Ser473) measurement. Total Akt was also measured to verify equivalent loading.
###end p 48
###begin title 49
###xml 44 51 44 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 60 64 <span type="species:ncbi:10090">mice</span>
Higher level of p-Akt in mammary tissues of NHERF1 knockout mice
###end title 49
###begin p 50
###xml 76 85 76 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 94 95 94 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 100 101 100 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 119 127 119 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 193 200 193 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 324 330 324 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 330 333 330 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 335 341 335 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 341 344 341 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 350 356 350 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 356 359 356 359 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 368 375 368 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 415 417 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 517 523 517 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 523 527 523 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 657 663 657 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 663 667 663 667 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 680 682 680 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 794 796 794 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 828 834 828 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 834 838 834 838 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 935 941 935 941 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 941 945 941 945 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 1016 1018 1016 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 1218 1224 1218 1224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 1224 1228 1224 1228 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 1301 1303 1301 1303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 1386 1393 1386 1393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 209 213 <span type="species:ncbi:10090">mice</span>
###xml 318 322 <span type="species:ncbi:10090">mice</span>
###xml 493 497 <span type="species:ncbi:10090">mice</span>
###xml 527 531 <span type="species:ncbi:10090">mice</span>
###xml 611 615 <span type="species:ncbi:10090">mice</span>
###xml 667 671 <span type="species:ncbi:10090">mice</span>
###xml 1208 1212 <span type="species:ncbi:10090">mice</span>
###xml 1228 1232 <span type="species:ncbi:10090">mice</span>
Knockout or knockdown of NHERF1 resulted in slower dephosphorylation of Akt in vitro (Figures 2 and 3). If this occurs in vivo as well, then an increase in p-Akt level would be expected in the NHERF1 knockout mice. To clarify this, we measured the p-Akt level in mammary gland specimens taken from the three groups of mice (NHERF1+/+, NHERF1+/-, and NHERF1-/-), whose NHERF1 genetic background was verified (Figure 4a). NHERF1 protein was also measured. Despite expressional variability among mice in the same group, NHERF1+/- mice had an overall lower NHERF1 protein level in mammary glands than did wild-type mice. No NHERF1 protein was detectable in the NHERF1-/- mice (Figure 4b). This finding was consistent with the NHERF1 expression pattern in kidney extracts among the three genotypes [31]. When p-Akt was measured, the NHERF1-/- mammary gland was shown to maintain a markedly higher p-Akt level in comparison with that of the NHERF1+/+ specimens, whereas the total Akt level remained little changed (Figure 4b). This result suggests that normal NHERF1 function involves suppression of Akt survival signaling by affecting the balance between PI3K and PTEN. Interestingly, compared with the wild-type mice, the NHERF1+/- mice exhibited a moderate but consistent increase in p-Akt level (Figure 4b), indicating that decreased NHERF1 expression resulting from deletion of a single NHERF1 allele may be sufficient to promote cell survival in the mammary gland.
###end p 50
###begin p 51
###xml 51 55 51 55 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 86 87 86 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 89 91 89 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 437 441 437 441 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
NHERF1 accelerates decay of p-Akt induced by PDGF. (a) MCF10A cells over-expressing Na+/H+ exchanger regulatory factor 1 (NHERF1) or control vector (Babe) were serum starved and restimulated with platelet-derived growth factor for 0 to 120 minutes as indicated. Cells were lysed for measurement of phospho-Akt (p-Akt) level by immunoblotting. Expression status of NHERF1 was verified. Total Akt was also determined to normalize loading. (b) Zr75.1 cells infected with NHERF1 knockdown vector (910) or control (Babe) were analyzed as described for panel a.
###end p 51
###begin p 52
###xml 48 55 48 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 70 74 70 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 88 95 88 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 155 161 155 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 161 164 161 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 166 172 166 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 172 175 172 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 181 187 181 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 187 191 187 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 211 215 211 215 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 64 68 <span type="species:ncbi:10090">mice</span>
###xml 104 108 <span type="species:ncbi:10090">mice</span>
###xml 191 195 <span type="species:ncbi:10090">mice</span>
###xml 314 318 <span type="species:ncbi:10090">mice</span>
Elevated phospho-Akt levels in mammary gland of NHERF1 knockout mice. (a) Genotyping of NHERF1 knockout mice. Numbers 1 to 3, 4 to 6, and 7 to 9 represent NHERF1+/+, NHERF1+/-, and NHERF1-/- mice, respectively. (b) Immunodetection of NHERF1 and phospho-Akt (p-Akt; Ser473) expression in mammary gland tissues from mice of respective genotypes. Membrane was stripped and reprobed with beta-actin to normalize loading. WT, wild-type.
###end p 52
###begin title 53
NHERF1 affects cell sensitivity to PDGFR inhibitor
###end title 53
###begin p 54
###xml 543 545 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 546 548 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 831 833 831 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 984 986 984 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 1138 1140 1138 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 440 448 <span type="species:ncbi:9606">patients</span>
Because NHERF1 markedly affected p-Akt turnover in response to PDGF stimulation, we surmised that NHERF1 expression status might also affect cell response to PDGFR inhibition. Zr75.1 cells with or without NHERF1 knockdown were treated with STI-571 for 2 days before MTT assay for surviving cells. STI-571 is a small molecule inhibitor of tyrosine kinases, including BCR-Abl, PDGFR and c-kit, and as a result it has been used effectively in patients with chronic myelogenous leukemia, gastrointestinal stromal tumor, and other types of tumors [33-35]. We first compared the Zr75.1 cells (base control and NHERF1 knockdown cells) in tems of their sensitivity to STI-571. While untreated, NHERF1 knockdown cells exhibited a modest increase in cell proliferation after 2 days of culture, which is in agreement with our earlier report [25]. When cells were treated with STI-571, we found that Zr75.1 cells with NHERF1 knockdown were much more resistant to STI-571 than the control (Figure 5a). Similarly, over-expression of NHERF1 in MCF10A cells rendered them more sensitive to STI-571 treatment than their corresponding Babe control (Figure 5b). These findings suggest that changes in cell survival signaling resulting from NHERF1 loss affect cell sensitivity to PDGFR blocker.
###end p 54
###begin p 55
###xml 46 50 46 50 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 197 201 196 200 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 232 233 231 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 235 237 234 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 559 561 557 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 572 574 570 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
NHERF1 increases cell sensitivity to STI-571. (a) Zr75.1 cells with NHERF1 knockdown (910) or Babe controls were cultured in 96-well plates and treated with STI-571 (10 and 30 mumol/l) for 2 days. (b) MCF10A cells over-expressing Na+/H+ exchanger regulatory factor 1 (NHERF1) or vector control were subjected to STI-571 treatment (3 and 10 mumol/l) for 2 days. MTT reagents were added to assess the relative number of surviving cells. The numbers of untreated Babe control were arbitrarily set at 100%. Data from five independent experiments are presented. **P < 0.01, ***P < 0.001 versus Babe control of the corresponding treatment.
###end p 55
###begin p 56
###xml 763 765 763 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6a</xref>
###xml 908 910 908 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 1081 1083 1081 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6b</xref>
###xml 1244 1246 1244 1246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
To determine whether apoptosis is involved in the cell density difference between NHERF1-positive and NHERF1-negative cells, we harvested the cells during STI-571 treatment and assayed cell lysates for cleaved forms of caspase-3, a marker of active apoptotic process. Immunoblottings showed that before STI-571 treatment, no cleaved caspase-3 isoforms were present in either the NHERF1 knock-down or the control Zr75.1 (Babe) cells. One day of STI-571 treatment resulted in significant increases in caspase-3 cleavage in Zr75.1 Babe control cells, suggesting that apoptosis is at least partially responsible for STI-571-induced growth inhibition. Interestingly, the same treatment led to markedly lower caspase-3 cleavage in NHERF1-knockdown Zr75.1 cells (Figure 6a), which is consistent with a decreased response to STI-571-induced cell death in comparison with that of NHERF1-positive Zr75.1 cells (Figure 5a). Similar experiments were carried out on MCF10A cells, in which we showed that over-expression of NHERF1 markedly enhanced STI-571-induced cleavage of caspase-3 (Figure 6b). All of these findings indicated that loss of NHERF1 may affect cell response to growth factor inhibition as a result of increases in intrinsic cell survival [36].
###end p 56
###begin p 57
###xml 69 73 69 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 84 88 84 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 114 115 114 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 117 119 117 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
NHERF1 increases caspase-3 cleavage in response to STI-571. Cultured (a) MCF10A and (b) Zr75.1 cells of varying Na+/H+ exchanger regulatory factor 1 (NHERF1) expression level were treated with STI-571 for 1 day. Cells were then lysed and separated by SDS-PAGE. Immunoblotting was used to detect caspase-3 (8G10). The caspase-3 antibody recognized both the full-length (35 kDa [arrow]) and the large fragment (17/19 kDa [arrowhead]) of caspase-3 resulting from cleavage.
###end p 57
###begin p 58
###xml 177 181 177 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN</italic>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7a</xref>
###xml 1403 1405 1403 1405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7b</xref>
To assess whether PTEN is required for the increased sensitivity to STI-571, we first determined whether altered NHERF1 expression level affected cell responses to STI-571 in a PTEN-null background. MDA-MB-468 cells are NHERF1 positive but lack PTEN as a result of homozygous deletion. We knocked down NHERF1 expression in MDA-MB-468 cells using siRNA retrovirus, and these cells were tested for STI-571 sensitivity. We found that in the absence of PTEN the NHERF1-knockdown cells responded to STI-571 at a level similar to that in Babe control cells (Figure 7a). We then determined whether PTEN knockdown was able to influence NHERF1-inducible sensitivity to STI-571 in MCF10A cells. NHERF1 expression (or Neo control) in MCF10A cells was retrovirally transduced and the resultant cells were subjected to PTEN knockdown through retrovirally delivered siRNA (or Babe control). These steps yielded four cell lines with varying PTEN and NHERF1 expression. These cells were then tested for STI-571 sensitivity. PTEN knockdown resulted in a modest increase in proliferation as compared with the control. As expected, over-expression of NHERF1 in parental cells elevated STI-571-inducible killing. In contrast, NHERF1 expression in cells with PTEN knockdown remained highly resistant to STI-571. These findings indicated that increased sensitivity to PDGFR inhibition by NHERF1 was dependent on PTEN (Figure 7b).
###end p 58
###begin p 59
###xml 72 76 72 76 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 161 162 161 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 164 166 164 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 444 448 443 447 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 768 770 766 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
PTEN is required for NHERF1-induced increase in sensitivity to STI-571. (a) Phosphatase and tensin homolog (PTEN)-negative MDA-MB-468 cells were infected with Na+/H+ exchanger regulatory factor 1 (NHERF1) small interfering RNA (siRNA; 910) or control (Babe) retrovirus. Their NHERF1 expression was measured by immunoblotting. Theses cells were treated with STI-571 (3 and 10 mumol/l) for 2 days. The cell survival was measured using MTT assay. (b) MCF10A cells with varying NHERF1 and PTEN levels through retroviral over-expression (NHERF1) or siRNA knockdown (PTEN-KD) were treated with 3 mumol/l STI-571 for 2 days before MTT assay. The reading of untreated control cells was arbitrarily set at 100%. Data from three to five independent experiments are presented (**P < 0.01).
###end p 59
###begin title 60
###xml 63 68 63 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN </italic>
###xml 71 77 71 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PI3KCA</italic>
LOH is correlated with lowered NHERF1 expression and wild-type PTEN or PI3KCA
###end title 60
###begin p 61
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 395 402 395 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 461 463 461 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 473 475 473 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
To explore whether LOH is responsible for a decrease in NHERF1 expression, we correlated the two parameters in 22 breast cancer cell lines that had been tested [15,25]. Among the six cell lines with a high NHERF1 expression level, five (83%) were found to be LOH negative. In contrast, of the 16 cell lines with low and no NHERF1 expression, only two (12.5%) were LOH negative. Thus, LOH at the NHERF1 locus is highly associated with lowered NHERF1 expression (P = 6.8 x 10-6, by Fisher's exact test).
###end p 61
###begin p 62
###xml 164 171 164 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 175 180 175 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN </italic>
###xml 184 190 184 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PI3KCA</italic>
###xml 231 238 231 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 261 265 261 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN</italic>
###xml 266 273 266 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PI3KCA </italic>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 419 426 419 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 477 482 477 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN </italic>
###xml 485 492 485 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PI3KCA </italic>
###xml 580 584 580 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN</italic>
###xml 585 592 585 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PI3KCA </italic>
###xml 633 638 633 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN </italic>
###xml 641 648 641 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PI3KCA </italic>
###xml 689 696 689 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 705 707 705 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
The physical and functional relation between NHERF1 and PTEN indicates they may exist in a common tumor suppressor pathway, which would predict segregation between NHERF1 and PTEN (or PI3KCA) alterations. We thus evaluated whether NHERF1 LOH is correlated with PTEN/PI3KCA mutational status. A total of 39 breast cancer cell lines with available genetic status were used for the correlative analyses [37]. Among the 23 NHERF1 LOH-positive cell lines, 15 (65%) had an unaltered PTEN or PI3KCA gene. In contrast, out of the 16 LOH-negative cell lines, only 4 (25%) showed wild-type PTEN/PI3KCA status. The genetic alteration in either PTEN or PI3KCA gene was strongly associated with intact NHERF1 alleles (P = 0.022, by Fisher's exact test).
###end p 62
###begin title 63
Discussion
###end title 63
###begin p 64
###xml 23 29 23 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 104 111 104 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 172 179 172 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 301 308 301 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 456 458 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 673 675 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 747 753 747 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 52 57 <span type="species:ncbi:9606">human</span>
###xml 166 171 <span type="species:ncbi:9606">Human</span>
Our earlier results of NHERF1genetic alterations in human breast cancer prompted us to hypothesize that NHERF1 acts as a tumor suppressor gene in mammary gland [15]. Human NHERF1 is an estrogen-inducible gene [36]. Estrogen response element half-sites have been located in the 5'-regulatory region of NHERF1 gene that are responsible for estrogen-stimulated expression [38]. Because estrogenic signaling is thought to be growth promoting in breast cancer [39], the suppressor activity of NHERF1 was somewhat unexpected. Although the roles of estrogenic induction in NHERF1 biology is not clear, we identified increased growth of breast cancer cells after NHERF1 knockdown [25], which is in agreement with the proposed tumor suppressor function of NHERF1. Here we provide additional evidence to support our overall hypothesis.
###end p 64
###begin p 65
###xml 622 628 622 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 628 632 628 632 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 645 646 645 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 679 686 679 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 863 865 863 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1045 1047 1045 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1048 1050 1048 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1127 1133 1127 1133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 1133 1137 1133 1137 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 632 636 <span type="species:ncbi:10090">mice</span>
###xml 1121 1125 <span type="species:ncbi:10090">mice</span>
###xml 1137 1141 <span type="species:ncbi:10090">mice</span>
In breast cells, NHERF1 expression accelerated the turnover of p-Akt induced by PDGF stimulation. This finding was obtained in both over-expression and knockdown models, from both immortalized normal mammary epithelial cells (MCF10A) and a breast cancer line (Zr75.1). The effect of NHERF1 to stimulate the decay of p-Akt is probably through PTEN recruitment by NHERF1 to the cytoplasmic membrane compartment, where active phosphorylation and dephosphorylation of Akt occur. The response is probably related to normal mammary biology, as indicated by the markedly increased levels of p-Akt in the mammary gland tissues of NHERF1-/- mice (Figure 4). Elevated p-Akt resulting from NHERF1 deletion presumably potentiates the cell survival pathway in mammary gland, where balanced survival and apoptotic signaling is essential for normal development and homeostasis [40]. A deregulated apoptotic process, which leads to defective structural organization and remodeling in mammary gland, is believed to be directly related to breast cancer etiology [41,42]. Interestingly, we recently found that, in contrast to the wild-type mice, NHERF1-/- mice exhibited increased ductal side branching and extensive alveolar hyperplasia in mammary gland (our unpublished data). Whether aberrant Akt activation is directly related to hyperplastic morphology in mammary gland warrants further investigation. Also remaining to be established is whether this impaired mammary development is sufficient to increase or accelerate the incidence of mammary tumor.
###end p 65
###begin p 66
###xml 42 49 42 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 527 529 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 530 532 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 601 608 601 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 713 720 713 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 852 859 852 859 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 880 888 880 888 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 926 933 926 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 1001 1003 1001 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1047 1054 1047 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 1132 1133 1132 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 1352 1358 1352 1358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 1358 1362 1358 1362 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 1410 1411 1410 1411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 1452 1458 1452 1458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 1458 1462 1458 1462 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 1532 1538 1532 1538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 1538 1542 1538 1542 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1755 1761 1755 1761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1</italic>
###xml 294 298 <span type="species:ncbi:10090">mice</span>
###xml 1362 1366 <span type="species:ncbi:10090">mice</span>
###xml 1462 1466 <span type="species:ncbi:10090">mice</span>
###xml 1542 1546 <span type="species:ncbi:10090">mice</span>
Because of the strong correlation between NHERF1 LOH and the aggressive features of breast cancer, we hypothesized that NHERF1 tumor suppressor activity was haploinsufficient [15]. A number of tumor suppressor genes have been shown to have haploinsufficient activities [43-46]. In these cases, mice carrying an inactivated allele are predisposed to tumor development, and the resulting tumors frequently retain a functional wild-type allele. Interestingly, two NHERF1-binding partners, namely PTEN and NF2, use this mechanism [43,44]. A lowered expression as a result of single allele deletion of the NHERF1 gene is obligatory for its haploinsufficient biology. In support of this mechanism, we found that LOH of NHERF1 locus in 22 breast cancer cell lines was strongly correlated with lowered NHERF1 protein level. The haploinsufficient expression of NHERF1 is also supported by in vivo observations. Monoallelic deletion of NHERF1 was shown to decrease NHERF1 expression in kidney epithelial cells [31]. Similarly, deletion of one allele of the NHERF1 gene resulted in decreased NHERF1 protein expression in mammary gland (Figure 4), providing a plausible link between altered protein expression level and the resultant phenotypic responses. We found lowered NHERF1 expression to be accompanied by a modest increase in p-Akt in the mammary tissue of NHERF1+/- mice as compared with that in wild-type (Figure 4). Coincidentally, the mammary glands of NHERF1+/- mice exhibited alveolar hyperplasia, albeit less extensively than the NHERF1-/- mice (our unpublished data). The correlation suggested an association between abnormal Akt activation and mammary hyperplasia, highlighting the biochemical and pathological consequences of monoallelic deletion of NHERF1.
###end p 66
###begin p 67
###xml 50 57 50 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 115 122 115 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 249 256 249 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
Our findings clearly indicated a dosage effect of NHERF1 activity during normal mammary gland development. Whether NHERF1 affects breast cancer susceptibility through the haploinsufficiency mechanism requires further investigation. Haploinsuficient NHERF1 tumor suppressor activity would also explain the relatively low frequency of intragenic mutations, although the possibility that other NHERF1 pathway components are genetically altered cannot be ruled out.
###end p 67
###begin p 68
###xml 447 454 447 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 488 493 488 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN </italic>
###xml 497 503 497 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PI3KCA</italic>
The present study verifies that NHERF1 has tumor suppressor activity, providing evidence to suggest that its function relies on an intact PTEN pathway. First, NHERF1 is associated with accelerated dephosphorylation of p-Akt, presumably through recruitment of PTEN by NHERF1. Second, knockdown of PTEN abolishes NHERF1-induced sensitivity to chemo-agents. If NHERF1 activity is dependent on PTEN, as our functional study had suggested, then intact NHERF1 should be associated with altered PTEN (or PI3KCA) gene in breast cancer. Our data from 39 breast cancer cell lines showed that this was indeed the case. Collectively, our present study indicates that NHERF1 binds to PTEN to downregulate the PI3K-Akt pathway to elicit tumor suppressor activity. Given that PTEN-PI3K-Akt is one of the most prominent pathways relevant to tumorigenesis and targeted therapy of almost all types of carcinoma, studies on NHERF1 should be instrumental to the development of new strategies to overcome chemo-resistance and enhance efficacy.
###end p 68
###begin p 69
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 600 602 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 707 709 707 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 586 591 <span type="species:ncbi:10090">mouse</span>
###xml 1015 1023 <span type="species:ncbi:9606">patients</span>
In this study we also present evidence that NHERF1 expression status significantly affects how cells respond to PDGFR inhibition. PDGF is among the key growth factors and cytokines that breast cancer cells produce via autocrine or paracrine mechanisms that contribute to malignant progression [47]. Activated PDGF signaling has been shown to prevent cells from undergoing apoptosis during epithelial mesenchymal transition and thus promote breast cancer progression and metastasis [48,49]. As a potent PDGFR inhibitor, STI-571 has been shown to inhibit breast cancer bone metastasis in mouse models [50], and it is being tested clinically in treatment of metastatic breast cancer, among other cancer types [51]. Although the exact mechanism responsible for improved susceptibility to STI-571 by NHERF1 needs further investigation, our present study indicates an inhibitory effect of NHERF1 on PDGF-medicated breast cancer progression and suggests that the status of NHERF1 expression in breast tumor influences how patients respond to STI-571. Because a majority of breast tumors lose NHERF1 expression, our present study raises a possibility of enhancing chemosensitivity by restoring NHERF1 expression. NHERF1 expression may also be used as a biomarker to predict the effectiveness of such treatment.
###end p 69
###begin title 70
Conclusion
###end title 70
###begin p 71
###xml 255 262 255 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NHERF1 </italic>
###xml 281 286 281 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN </italic>
###xml 289 296 289 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PI3KCA </italic>
In this report, we show that, by interacting with PTEN, NHERF1 accelerates the turnover of p-Akt and enhances the cell sensitivity to STI-571. That NHERF1 elicits suppressor function through PTEN is also indicated by an inverse correlation between intact NHERF1 gene and wild-type PTEN or PI3KCA in breast cancer cells. Given the critical roles of Akt in cell survival and tumorigenesis, the negative regulatory effect of NHERF1 on Akt activity is highly relevant to NHERF1 mammary tumor suppressor function. Our finding of a higher sensitivity of breast cells to STI-571 in the presence of NHERF1 suggests that future investigations of this important pathway may yield new measures to improve breast cancer treatment.
###end p 71
###begin title 72
Abbreviations
###end title 72
###begin p 73
###xml 203 204 203 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 206 208 206 208 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 97 102 <span type="species:ncbi:10090">mouse</span>
ERM = ezrin-radixin-moesin; GST = glutathione S-transferase; LOH = loss of heterozygosity; MEF = mouse embryonic fibroblast; MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NHERF = Na+/H+ exchanger regulatory factor; p-Akt = phospho-Akt; PCR = polymerase chain reaction; PDGFR = platelet-derived growth factor receptor; PI3K = phosphoinositide-3 kinase; PTEN = phosphatase and tensin homolog; siRNA = small interfering RNA.
###end p 73
###begin title 74
Competing interests
###end title 74
###begin p 75
The authors declare that they have no competing interests.
###end p 75
###begin title 76
Authors' contributions
###end title 76
###begin p 77
YP designed the experiments, carried out technical procedures, and interpreted the data. EJW provided the knockout animals and edited the manuscript. JLD designed the experiments, interpreted the results and wrote the manuscript. All authors approved the final manuscript.
###end p 77
###begin title 78
Acknowledgements
###end title 78
###begin p 79
The authors thank Drs Jinsong Liu and Charles Sawyer for sharing DNA constructs. This work was supported by the grants from NIH R01-CA100278 (JLD), P50-CA116199 (JLD) and R01-DK55881 (EJW), a grant from Institutional Research Program of MDACC (JLD), and a Research Service grant from the Department of Veterans Affairs (EJW).
###end p 79
###begin article-title 80
###xml 58 59 58 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 61 63 61 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
cAMP-mediated inhibition of the epithelial brush border Na+/H+ exchanger, NHE3, requires an associated regulatory protein
###end article-title 80
###begin article-title 81
###xml 62 63 62 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 65 67 65 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
CAMP-mediated inhibition of the renal brush border membrane Na+-H+ exchanger requires a dissociable phosphoprotein cofactor
###end article-title 81
###begin article-title 82
A NHERF binding site links the betaPDGFR to the cytoskeleton and regulates cell spreading and migration
###end article-title 82
###begin article-title 83
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 62 64 62 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Platelet-derived growth factor receptor association with Na+/H+ exchanger regulatory factor potentiates receptor activity
###end article-title 83
###begin article-title 84
Regulation of cystic fibrosis transmembrane conductance regulator single-channel gating by bivalent PDZ-domain-mediated interaction
###end article-title 84
###begin article-title 85
Peptide binding consensus of the NHERF-PDZ1 domain match the C-terminal sequence of cystic fibrosis transmembrane conductance regulator (CFTR)
###end article-title 85
###begin article-title 86
An apical PDZ protein anchors the cystic fibrosis transmembrane conductance regulator to the cytoskeleton
###end article-title 86
###begin article-title 87
A kinase-regulated PDZ-domain interaction controls endocytic sorting of the beta2-adrenergic receptor
###end article-title 87
###begin article-title 88
###xml 51 52 51 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 54 55 54 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 97 98 97 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 100 102 100 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
The beta2-adrenergic receptor interacts with the Na+/H+-exchanger regulatory factor to control Na+/H+ exchange
###end article-title 88
###begin article-title 89
Roles of the matrix metalloproteinase in mammary gland development and cancer
###end article-title 89
###begin article-title 90
###xml 58 59 58 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 61 63 61 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
G protein-coupled receptor kinase 6A phosphorylates the Na+/H+ exchanger regulatory factor via a PDZ domain-mediated interaction
###end article-title 90
###begin article-title 91
###xml 51 52 51 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 54 56 54 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Regulation of phospholipase C-beta 3 activity by Na+/H+ exchanger regulatory factor 2
###end article-title 91
###begin article-title 92
Yes-associated Protein 65 localizes p62c-Yes to the apical compartment of airway epithelia by association with EBP50
###end article-title 92
###begin article-title 93
Association of mammalian Trp4 and phospholipase C isozymes with a PDZ domain-containing protein, NHERF
###end article-title 93
###begin article-title 94
###xml 9 10 9 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 12 14 12 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 61 66 <span type="species:ncbi:9606">human</span>
NHERF (Na+/H+ exchanger regulatory factor) gene mutations in human breast cancer
###end article-title 94
###begin article-title 95
Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2
###end article-title 95
###begin article-title 96
A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor
###end article-title 96
###begin article-title 97
###xml 17 22 <span type="species:ncbi:9606">human</span>
Allelotype of 28 human breast cancer cell lines and xenografts
###end article-title 97
###begin article-title 98
A region of interstitial 17q25 allelic loss in ovarian tumors coincides with a defined region of loss in breast tumors
###end article-title 98
###begin article-title 99
Detailed deletion analysis of sporadic breast tumors defines an interstitial region of allelic loss on 17q25
###end article-title 99
###begin article-title 100
17q21-q25 aberrantions in breast cancer: combined allelotyping and CGH analysis reveals 5 regions of allelic imbalance among which two correspond to DNA amplification
###end article-title 100
###begin article-title 101
Four regions of allelic imbalance on 17q12-qter associated with high-grade breast tumors
###end article-title 101
###begin article-title 102
Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q
###end article-title 102
###begin article-title 103
###xml 57 58 57 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 60 62 60 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Phosphorylation and cell cycle-dependent regulation of Na+/H+ exchanger regulatory factor-1 by Cdc2 kinase
###end article-title 103
###begin article-title 104
###xml 46 47 46 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 49 51 49 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Suppression of breast cancer cell growth by Na+/H+ exchanger regulatory factor 1 (NHERF1)
###end article-title 104
###begin article-title 105
PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling
###end article-title 105
###begin article-title 106
Implication of the MAGI-1b/PTEN signalosome in stabilization of adherens junctions and suppression of invasiveness
###end article-title 106
###begin article-title 107
Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2
###end article-title 107
###begin article-title 108
Interaction of the tumor suppressor PTEN/MMAC with a PDZ Domain of MAGI3, a novel membrane-associated guanylate kinase
###end article-title 108
###begin article-title 109
Inhibition of protein kinase B/Akt. implications for cancer therapy
###end article-title 109
###begin article-title 110
###xml 27 32 <span type="species:ncbi:10090">mouse</span>
Targeted disruption of the mouse NHERF-1 gene promotes internalization of proximal tubule sodium-phosphate cotransporter type IIa and renal phosphate wasting
###end article-title 110
###begin article-title 111
Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer
###end article-title 111
###begin article-title 112
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
###end article-title 112
###begin article-title 113
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
###end article-title 113
###begin article-title 114
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
###end article-title 114
###begin article-title 115
###xml 38 39 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 41 43 41 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Estrogen receptor regulation of the Na+/H+ exchanger regulatory factor
###end article-title 115
###begin article-title 116
###xml 61 66 <span type="species:ncbi:9606">human</span>
Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines
###end article-title 116
###begin article-title 117
###xml 46 47 46 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 49 51 49 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 38 43 <span type="species:ncbi:9606">human</span>
Estrogen receptor inducibility of the human Na+/H+ exchanger regulatory factor/ezrin-radixin-moesin binding protein 50 (NHE-RF/EBP50) gene involving multiple half-estrogen response elements
###end article-title 117
###begin article-title 118
Expanding the role of NHERF, a PDZ-domain containing protein adaptor, to growth regulation
###end article-title 118
###begin article-title 119
###xml 12 17 <span type="species:ncbi:10090">mouse</span>
An atlas of mouse mammary gland development
###end article-title 119
###begin article-title 120
###xml 40 46 <span type="species:ncbi:10090">murine</span>
Apoptosis in the terminal endbud of the murine mammary gland: a mechanism of ductal morphogenesis
###end article-title 120
###begin article-title 121
Apoptosis in cancer
###end article-title 121
###begin article-title 122
Pten is essential for embryonic development and tumour suppression
###end article-title 122
###begin article-title 123
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors
###end article-title 123
###begin article-title 124
Chk1 is haploinsufficient for multiple functions critical to tumor suppression
###end article-title 124
###begin article-title 125
Haplo-insufficiency of BRCA1 in sporadic breast cancer
###end article-title 125
###begin article-title 126
Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis
###end article-title 126
###begin article-title 127
Autocrine PDGFR signaling promotes mammary cancer metastasis
###end article-title 127
###begin article-title 128
PDGF receptors as targets in tumor treatment
###end article-title 128
###begin article-title 129
###xml 88 93 <span type="species:ncbi:9606">human</span>
###xml 123 132 <span type="species:ncbi:10090">nude mice</span>
Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice
###end article-title 129
###begin article-title 130
###xml 53 61 <span type="species:ncbi:9606">patients</span>
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer
###end article-title 130

